Evidence map›Paper›PMID 40263416›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Chronic, combinatorial targeting of NMDARs and 5-HT

Briana K Chen, Alicia Whye, Louise C Matthews, Taylor Moniz, Indira Mendez-David, Alain M Gardier, Denis J David, Stefanie Johns, Eric Weisblum, Christine A Denny

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Combinatorial targeting of NMDARs and 5-HTAlzheimer's research & therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Briana K ChenDoctoral Program in Neurobiology and Behavior (NB&B), Columbia University, New York, NY, 10027, USA.ORCID http://orcid.org/0000-0003-1982-1389
Alicia WhyeDepartment of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA.
Louise C MatthewsDepartment of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA.
Taylor MonizSchool of General Studies, Columbia University, New York, NY, 10027, USA.
Indira Mendez-DavidUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri MOISSAN, Orsay, FRA, France.
Alain M GardierUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri MOISSAN, Orsay, FRA, France.
Denis J DavidUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri MOISSAN, Orsay, FRA, France.ORCID http://orcid.org/0000-0002-0506-6688
Stefanie JohnsSilo Pharma, Sarasota, FL, 34236, USA.
Eric WeisblumSilo Pharma, Sarasota, FL, 34236, USA.
Christine A DennyDepartment of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA. cad2125@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-6926-2020

Funding

Identification and Pharmacological Manipulation of Fear Overgeneralization Neural Ensembles following Traumatic Brain Injury (TBI)R21NS114870 · NINDS · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI DENNY, CHRISTINE ANN · 2020 to 2020
$446k
Brain and Behavior Research Foundation (Brain & Behavior Research Foundation) 2017 GrantNINDS NIH HHS R21 NS114870U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 1 NS114870
6 · The paper itself

Abstract

Serotonin (5-HT) receptors and N-methyl-D-aspartate receptors (NMDARs) have both been implicated in stress-induced psychiatric disorders. However, there is a paucity of studies evaluating the effectiveness of novel combinatorial pharmacological treatments to treat stress-related disorders. Here, we evaluated whether administration of combinatorial (R,S)-ketamine, an NMDAR antagonist and Food and Drug Administration (FDA)-approved anesthetic, and prucalopride, a 5-HT type IV receptor (5-HT

Indexed as

Excitatory Amino Acid AntagonistsReceptors, N-Methyl-D-AspartateReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor AgonistsStress, PsychologicalAnimalsBehavior, AnimalBenzofuransCorticosteroneDrug Therapy, CombinationKetamineMaleRatsRats, Sprague-DawleyBenzofuransCorticosteroneExcitatory Amino Acid AntagonistsKetamineprucaloprideReceptors, N-Methyl-D-AspartateReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor Agonists

Identifiers

PMID40263416
PMCPMC12170899

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.